Loading...
Loading...
TSBX| Name | Value |
|---|---|
| Revenues | 2.0M |
| Cost of Revenue | 1.0M |
| Gross Profit | 1.0M |
| Operating Expense | 11.9M |
| Operating I/L | -11.4M |
| Other Income/Expense | -0.7M |
| Interest Income | 0.0M |
| Pretax | -12.0M |
| Income Tax Expense | 0.8M |
| Net Income/Loss | -12.9M |
Turnstone Biologics Corp. is a clinical stage biotechnology company specializing in developing innovative medicines for the treatment and cure of solid tumors. The company's lead product, TIDAL-01, is currently in Phase 1 clinical trials for breast cancer, colorectal cancer, uveal melanoma, and an investigator sponsored trial for cutaneous and non-cutaneous melanomas. Additionally, Turnstone Biologics Corp. is advancing TIDAL-02 through preclinical development for the treatment of solid tumors.
